Tic disorder possibly related to the duration of action of short-acting methylphenidate in a seven-year-old child with attention deficit hyperactivity disorder and intellectual disability
Öz
Attention Deficit Hyperactivity Disorder (ADHD) is known to be seen more frequently in children diagnosed with intellectual disability than in children with normal development. Methylphenidate is a psychostimulant drug that is widely used in the treatment of ADHD. Recent randomized studies have reported that the use of methylphenidate is not associated with new onset or worsening of tics. However, studies on the effects of methylphenidate use in children with mental retardation are limited. The case is here presented of a 7-year-old male patient with borderline intellectual disability, who developed new-onset tics most likely due to methylphenidate treatment and whose tics subsided when the methylphenidate was discontinued and its effects subsided.
Anahtar Kelimeler
Methylphenidate, Intellectual Disability, Tic Disorder, Attention Deficit Hyperactivity Disorder, Child.
Destekleyen Kurum
The research has no funding.
Etik Beyan
Ethics committee approval is not required for case report articles.
Teşekkür
The author wishes to thank the patient and his parents who participated in this study.
Kaynakça
- Neece CL, Baker BL, Crnic K, Blacher J. Examining the validity of ADHD as a diagnosis for adolescents with intellectual disabilities: Clinical presentation. J Abnorm Child Psychol. 2013;41:597-612.
- Perera B. Attention deficit hyperactivity disorder in people with intellectual disability. Ir J Psychol Med. 2018;35:213-9.
- Tarrant N, Roy M, Deb S, Odedra S, Retzer A, Roy A. The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: A systematic review. Res Dev Disabil. 2018;83:217-32.
- Miller J, Perera B, Shankar R. Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Expert Opin Pharmacother. 2020;21:1897-913.
- Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54:28-736.
- Ogundele MO, Ayyash HF. Review of the evidence for the management of co-morbid tic disorders in children and adolescents with attention deficit hyperactivity disorder. World J Clin Pediatr. 2018;7:36-42
- Herrik KF, Redrobe JP, Holst D, Hougaard C, Sandager-Nielsen K, Nielsen AN et al. CyPPA, a positive SK3/SK2 modulator, reduces activity of dopaminergic neurons, inhibits dopamine release, and counteracts hyperdopaminergic behaviors induced by methylphenidate. Front Pharmacol. 2012;3:11.
- Ihezie SA, Thomas MM, Dafny N. Acute and chronic methylphenidate administration in intact and VTA-specific and nonspecific lesioned rats. J Neural Transm (Vienna). 2019;126:173-82.
- Felling RJ, Singer HS. Neurobiology of tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31:12387-95.
- Faraone SV.The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.
